A Hybrid Predictive Ensemble of Machine Learning and Deep Neural Networks for Early Cardiovascular Disease Risk Assessment
A study introduces an intelligent framework integrating machine learning and deep neural network ensemble techniques for early cardiovascular disease detection. It uses real-time physiological data from Internet of Medical Things (IoMT) devices, including ECG sensors, heart rate monitors, and blood pressure trackers. Preprocessing includes noise reduction, normalization, and missing value imputation. Feature selection identifies significant health indicators, processed by optimized classifiers such as SVM, Random Forests, and XGBoost combined in an ensemble. The framework achieves higher accuracy, reduced false positives, and enhanced consistency compared to conventional methods. It is designed on a cloud-based infrastructure for scalability and real-time continuous patient monitoring.
A research paper proposes a hybrid predictive ensemble combining machine learning and deep neural networks for early cardiovascular disease risk assessment. The system leverages IoMT data and cloud infrastructure for real-time monitoring, demonstrating improved diagnostic precision over conventional methods.
The ensemble architecture combines SVM, Random Forests, and XGBoost after feature selection, likely improving robustness and reducing overfitting. Cloud-based design suggests potential for distributed inference and scalability, though specific model details and performance metrics are not fully provided in the evidence.
This approach aligns with growing interest in AI-driven remote patient monitoring and preventive healthcare. Integration with IoMT devices indicates potential for deployment in wearable health tech and telemedicine platforms, though commercial readiness is not established.
If validated, the framework could reduce healthcare costs through early detection and continuous monitoring, create opportunities for cloud-based health analytics services, and enhance value propositions of IoMT device ecosystems.
Next observable signals include publication of full experimental results, validation on larger diverse datasets, and potential partnerships with healthcare providers or IoMT device manufacturers. Regulatory approval and clinical trials would be necessary for real-world deployment.